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The enzymes 6-methylsalicylic acid (6-MSA) syn-
thases (6-MSASs) are involved in the building of an
aryl moiety in many bioactive secondary metabolites
produced by fungi and bacteria. Using the bacterial
6-MSAS ChlB1 in the biosynthesis of spirotetronate
antibiotic chlorothricin (CHL) as a model, functional
analysis of its dehydratase (DH) and ketoreductase
(KR) domains by site-specific mutagenesis revealed
that selective ketoreduction is not essential for poly-
ketide chain extension. Promiscuity of the ketoacyl-
synthase domain in b functionality recognition allows
for engineering ChlB1 to an orsellinic acid (OSA)
synthase (OSAS) by inactivating KR at the active
site. The engineered ChlB1 is compatible with the
enzymes for late-stage tailoring in CHL biosynthesis,
featuring specific protein recognitions that facilitate
variable aryl group incorporation. The resulting spi-
rotetronates, which bear an OSA-derived aryl group,
exhibited antibacterial activities comparable to those
of the parent products.
INTRODUCTION
The enzymes 6-methylsalicylic acid (6-MSA) synthases (6-
MSASs) belong to a class of polyketide synthases (PKSs) that
are structurally type I but act iteratively for aromatic polyketide
biosynthesis (Fujii, 1999; Shen, 2000; Hertweck, 2009). They
consist of multiple functional domains, including the ketoacyl-
synthase (KS), acyltransferase (AT), dehydratase (DH), ketore-
ductase (KR), and acyl carrier protein (ACP) on a single protein
(Figure 1A). In a process resembling fatty acid biosynthesis,
6-MSASs catalyze the assembly of a nascent tetraketide from
one acetyl-CoA and three malonyl-CoAs by successive decar-
boxylative condensations. However, they clearly differ from fatty
acid synthases in processing the b-oxo functionality and
furnishing the product (Figure 1B), as (1) the KR domain selec-
tively reduces the b-keto group only on the growing triketide
intermediate 1 to give 2, followed by the cognate DH domain-
catalyzed dehydration to form a double bond of 3; and (2) theChemistry & Biology 17,tetraketide intermediate 4 undergoes intramolecular aldol
condensation, dehydration, and aromatization to afford 6-MSA.
Fungal 6-MSASs, along with other iterative PKS model
systems such as the nonreducing PksA in aflatoxin biosynthesis
(Crawford et al., 2008, 2009) and highly reducing LovB in lova-
statin biosynthesis (Kennedy et al., 1999; Ma et al., 2009), have
been extensively investigated to access the mechanisms for
chain-length control, regiospecific reduction, substrate toler-
ance, and subunit-domain interaction (Dimroth et al., 1976;
Beck et al., 1990; Spencer and Jordan, 1992; Bedford et al.,
1995; Fujii et al., 1996; Kealey et al., 1998; Richardson et al.,
1999; Moriguchi et al., 2006, 2008). Recently, 6-MSASs have
beenwidely found in bacteria, such as ChlB1 from Streptomyces
antibioticus (Jia et al., 2006; Shao et al., 2006), MdpB from Acti-
nomadura madurae (Van Lanen et al., 2007), PokM1 from S. dia-
statochromogenes (Daum et al., 2009), and PtmQ from S.
pactum (Ito et al., 2009), and are involved in the incorporation
of a 6-MSA derivative moiety into a number of structurally
diverse, bioactive secondary metabolites (see Figure S1A
available online). Fungal and bacterial 6-MSASs share high
homologies in sequence and domain organization, suggesting
their relationship in evolution (Figure S1B). Previous biochemical
studies on fungal 6-MSASs confirmed their KR domain function:
the native protein in the absence of NADPH or the KR mutant
enzyme with the inactivated NADPH binding site synthesizes
a shunt triketide compound (Figure 1B), triacetic acid lactone
(TAL), indicating the selective action of the KR domain for
reducing the b-keto group of the intermediate 1. However, it is
inconclusive whether 1 has to be reduced before reacting with
the third malonyl-CoA for proceeding further, despite no tetrake-
tide compound being identified. The reductive control in polyke-
tide chain elongation is not stringent for reactions catalyzed by
noniterative type I PKSs, as alterations of b-keto functionalities
can often be achieved on polyketides by modulating the activity
of the KR, DH, or enoylreductase (ER) domain in modules during
the growing process (McDaniel et al., 2005). Similar to this,
orsellinic acid (OSA) biosynthesis in bacteria, also catalyzed by
iterative type I PKSs, requires no reduction step in the process
of tetraketide intermediate (6) assembly (Figure 1B). OSA syn-
thases (OSASs), including AviM in avilamycin biosynthesis
(Gaisser et al., 1997) and CalO5 in calicheamicin biosynthesis
(Figure S1) (Ahlert et al., 2002), are composed of the KS, AT,
DH, and ACP domains (Figure 1A), displaying a head-to-tail
homology to 6-MSASs with the only exception of the omission495–503, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 495
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Figure 1. 6-Methylsalicylic Acid Synthase and Orsellinic Acid Synthase, and Biosyntheses of 6-MSA, Triacetic Acid Lactone, and Orsellinic
Acid
(A) Domain organizations of 6-methylsalicylic acid synthase (6-MSAS) and orsellinic acid synthase (OSAS). KS, ketoacylsynthase; AT, acyltransferase; DH,
dehydratase; KR, ketoreductase; ACP, acyl carrier protein.
(B) Pathways for 6-MSA synthesized by 6-MSASs and DH mutant ChlB1 (H947F), for triacetic acid lactone (TAL) synthesized by KR-mutated fungal 6-MSASs
(AxPxxA at the NADPH binding site), and for orsellinic acid (OSA) synthesized by OSASs AviM, CalO5, and KR-mutated ChlB1 (Y1450F at the active site). For
6-MSASs, solid arrows indicate native enzyme-catalyzed reactions, and dashed arrows showed the shunt reactions catalyzed by mutant enzymes.
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Engineered MSAS for Spirotetronate Generationof the KR domain. This implies that KR-catalyzed reduction for
iterative type I PKSs in aromatic polyketide biosynthesis may
not be essential for polyketide chain extending, but remains to
be confirmed experimentally.
Incorporation of the 6-MSA moiety into natural products
requires pathway-specific enzymes for PKS postmodification
and incorporation. We have recently dissected two distinct acyl-
transfer reactions centered on the acyl-S-ACP intermediate for
introducing the 6-MSA moiety to the biosynthesis of spirotetro-
nate antibiotic chlorothricin (CHL) (He et al., 2009). The 6-MSA
moiety from the 6-MSAS ChlB1 is transferred by the first AT496 Chemistry & Biology 17, 495–503, May 28, 2010 ª2010 ElsevierChlB3 onto the discrete ACP ChlB2, which may serve as a plat-
form for O-methylation and optional chlorination, and is then
appended to the terminal D-olivose unit by the second AT
ChlB6 (see below). Given that the ACP-mediated strategy
commonly facilitates the molecular recognition of downstream
enzymes (Freitag et al., 2005; Van Lanen et al., 2005; Singh
et al., 2007; Balibar et al., 2007; Fridman et al., 2007; Heide,
2009), the ACP-tethered, diverse aryl groups (2-methoxy-6-
methyl-benzoyl and its 5-chlorinated derivative) are readily
transferred and incorporated into the final molecule to afford de-
schloro-CHL and CHL, respectively. The advantage of effectiveLtd All rights reserved
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Figure 2. Functional Validation of DH or KR Mutant ChlB1 Derivatives in S. albus
HPLC analysis of the products from the negative control TL1006 (carrying the vector pTGV-2) (I); standard 6-MSA (II, asterisk); TL1071 for the native ChlB1 (III);
TL1072 for the DHmutant with H947A (IV); TL1073 for the DHmutant with H947F (V); standard TAL (VI, dot); standard OSA (VII, triangle); TL1074 for the KRmutant
with G1389A (VIII); TL1075 for the KR mutant with G1387A, G1389P, and G1392A (XI); and TL1076 for the KR mutant with Y1540F (X).
Chemistry & Biology
Engineered MSAS for Spirotetronate Generationprotein-protein interactions can be taken to alter the aryl func-
tionality for structural diversity.
Here, upon investigation into the functions of the DH and KR
domains by using the bacterial 6-MSAS ChlB1 as a model, we
report success in the engineering of this iterative type I PKS
into an OSAS by inactivating KR at the active site and show
the dispensability of the selective ketoreduction in polyketide
chain extending. More excitingly, this engineered ChlB1 for
OSA biosynthesis can effectively collaborate with downstream
enzymes in the CHL biosynthetic pathway, allowing for the
altered aryl moiety transfers and modifications to generate new
spirotetronates which showed biological activities at least
comparable to those of the parent compounds CHL and
deschloro-CHL.
RESULTS AND DISCUSSION
Heterologous Expression of chlB1 in Streptomyces
albus for 6-MSA Production
We first developed an approach to investigate in vivo the
domain functions of bacterial 6-MSAS by heterologous expres-
sion of chlB1 in S. albus. Although 6-MSA production was
previously detected by expressing chlB1 in S. lividans (Shao
et al., 2006), the poor yield (0.2–0.4 mg/L) may largely impede
progress for identifying the putative products of mutant ChlB1
derivatives in this host system. The DNA fragments encoding
the functional domain(s) (i.e., KS, AT, DH, and KR-ACP) wereChemistry & Biology 17,individually amplified by PCR. After sequencing to confirm the
fidelity, we assembled these fragments in chlB1 under the
control of the constitutive promoter PermE*. The strategy used
here facilitates the introduction of site-specific mutations into
the target domain of ChlB1. Further introduction of the resulting
construct into S. albus was carried out, giving the recombinant
strain TL1071 for product detection along with the control
S. albus strain AL1006 that carries the vector pTGV2 (Zhao
et al., 2008). HPLC-MS analysis showed that TL1071 produces
6-MSA (Figure 2, III), with an improved yield of z2.0 mg/L.
Consistent with our previous finding, the 6-MSA moiety syn-
thesized by ChlB1 is readily hydrolyzed to give the free acid
without functional association of downstream enzymes for
transfer (Shao et al., 2006). This method was therefore applied
in the following studies to probe the activities of the DH and KR
domains of ChlB1.
Effects of DH Domain Inactivation on 6-MSA Production
Sequence alignment of ChlB1 with various iterative type I PKSs
revealed a highly conserved motif in the DH domain,
HxxxGxxxxP, in which the His residue, corresponding to
His947 of ChlB1, is located at the active site (Figure S1B)
(Aparicio et al., 1996). To inactivate the DH domain of ChlB1,
we replaced His947 by site-specific mutagenesis with Ala and
Phe, according to the strategies previously used for functional
studies of the iterative fungal 6-MSAS ATX and the noniterative
PKS in picromycin biosynthesis (Wu et al., 2005; Moriguchi495–503, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 497
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Engineered MSAS for Spirotetronate Generationet al., 2008). The constructs were then introduced into S. albus,
yielding the recombinant strains TL1072 (for H947A substitution)
and TL1073 (for H947F substitution). Similar to that observed
from the corresponding H939A DH mutant ATX, the mutation
of H947A in ChlB1 completely abolished 6-MSA production in
TL1072 (Figure 2, IV). Interestingly, TL1073, harboring the
construct for expressing the H947F DH mutant ChlB1, still
produced 6-MSAwith a yield ofz0.4 mg/L (Figure 2, V), approx-
imately one fifth that produced by TL1071. The decrease in enzy-
matic activity of DH cannot be excluded in this H947F mutation;
alternatively, this finding indicates that the dehydration activity of
the ChlB1-DH domain is important but may not be indispensable
for producing 6-MSA, given that the proposed tetraketide inter-
mediate 5 could undergo an intramolecular cyclization followed
by spontaneous dehydrations to furnish the relatively stable
aromatic compound 6-MSA (Figure 1B). If so, H947A
substitution may significantly change a certain conformation of
the protein for display of enzymatic activity.
Effects of KR Domain Inactivation on Polyketide Chain
Elongation
We initially chose to mutate the NADPH binding site of the
ChlB1-KR domain, which features a highly conserved GxGxxG
motif in the well-known Rossmann fold (Figure S1B) (Chen
et al., 1990; Rescigno and Perham, 1994). This motif was
replaced via a single substitution of the second Gly residue (cor-
responding to Gly1389) to give GxAxxG, or via triple substitution
of all three Gly residues (corresponding to Gly1387, Gly1389,
and Gly1392) to yield AxPxxA, as previously used in the func-
tional analysis of fungal 6-MSASs by site-specific mutagenesis
(Richardson et al., 1999; Moriguchi et al., 2008). These replace-
ments resulted in the complete abolition of 6-MSA production in
the recombinant strains TL1074 (for GxAxxG mutation of ChlB1)
and TL1075 (for AxPxxA mutation of ChlB1) (Figure 2, VIII and IX,
respectively), consistent with findings in the studies of fungal
6-MSASs. TAL was not detectable in either strain, although
this shunt triketide product had been seen in the mutated fungal
6-MSASs. The polyketide nonproducing fact could be simply
referred to as binding of the cofactor NADPH may be necessary
for the enzyme tomaintain an active conformation. To avoid such
a potential change of protein without NADPH binding, we then
chose to mutate the highly conserved Tyr residue (correspond-
ing to Tyr1540 of ChlB1), which is located at the active site of
the KR domain, for forming a catalytic triad along with the Lys
and Ser residues (Figure S1B) (Reid et al., 2003; Caffrey, 2003;
Wu et al., 2005). The samemutation has been conducted to elim-
inate the KR activity of module 6 of the type I noniterative PKS
6-deoxyerythronolide B (DEB) synthase, showing that further
tailoring of the polyketide intermediate proceeds to afford the
3-keto derivative of DEB (Reid et al., 2003). Intriguingly,
Y1540F substitution in ChlB1 led to the accumulation of a distinct
product (0.4 mg/L, comparable to that of 6-MSA production of
TL1073) in the recombinant strain TL1076 (Figure 2, X). This
compound is identical to OSA, supported by high-resolution
electron impact mass spectrometry (HR-EI-MS) analysis (M+
ion at m/z = 168.0424, 168.0423 calculated) and using an
authentic compound as the standard. These findings confirmed
the selective reduction activity of the ChlB1-KR domain and,
more importantly, indicated that the third extending step indeed498 Chemistry & Biology 17, 495–503, May 28, 2010 ª2010 Elsevierproceeds on the unreduced triketide intermediate 1 to yield 6
(Figure 1B), followed by cyclization, dehydration, and aromatiza-
tion to give the final product as OSA which bears an additional
C-4 hydroxyl group in comparison to 6-MSA.
For bacterial iterative type I PKSs in aromatic polyketide
formation, we have proposed the catalytic nature of their
KR-DH pairs (Shao et al., 2006; Zhao et al., 2008). According
to a model for predicting the geometry of double bonds in poly-
ketide intermediates, cis double bonds arise from L-hydroxyacyl
precursors (Wu et al., 2005; Keatinge-Clay, 2007). Because the
ChlB1-KR domain lacks the His residue at the active site and
the characteristic L-D-D motif, ketoreduction is predicted to
yield the L-hydroxyacyl intermediate (2) (Keatinge-Clay, 2007).
The cis double bond could then be formed by the paired DH
domain, facilitating the folding of the polyketide intermediate
4 to furnish the cyclic structure by aldol condensation
(Figure 1B). The ChlB1 mutant lacking DH or KR activity retains
the ability to extend the intermediate to a tetraketide (5 or 6),
showing that the KS domain is indiscriminate in b functionality
recognition because variable triketides (2, 3, and 6) can serve
as substrates; but without structural constraint of the cis double
bond, the resulting hydroxyl- or oxo-acyl backbone might be
flexible, disfavoring folding and production. The yields of
6-MSA and OSA decrease to a similar level (z0.4 mg/L) in the
strains for expressing active DH-mutated ChlB1 (H947F) and
KR-mutated ChlB1 (Y1540F), respectively, consistent with this
prediction. Functional analysis of the DH and KR activities of
ChlB1 supports a common paradigm for 6-MSA biosynthesis
in bacteria and fungi, although OSA production has not been
validated by inactivating the KR domain of fungal 6-MSAS at
the active site.
Replacement of 6-MSAS by OSAS in the CHL
Biosynthetic Pathway for New Spirotetronate
Antibiotic Production
We have inactivated chlB1 by gene replacement and identified
the intermediate as DM-CHL (lacking the 6-MSA derivative
moiety) (Figure 3) from the mutant strain TL1012 (Jia et al.,
2006; Shao et al., 2006). Introduction of an intact chlB1 into
TL1012 was also carried out, leading to the conversion of
DM-CHL to CHL. Using this well-established in trans comple-
mentation system, we investigated whether the variable aryl
moiety can be transferred, modified, and eventually appended
to DM-CHL to make new spirotetronates. The construct that
encodes the engineered ChlB1 with Y1450F for OSA biosyn-
thesis was introduced into TL1012, giving the recombinant strain
TL1077 for product examination. HPLC-MS analysis of the crude
extract from 25 L of solid fermentation culture revealed two
distinct products, 7 and 8 (Figure 4, III), which exhibit ultraviolet
absorption patterns quite similar to those of deschloro-CHL and
CHL (Figure S3A). For structural elucidation, compounds 7 and 8
were purified and subjected to comparative spectroscopic anal-
ysis with the parent compound CHL. High-resolution electro-
spray mass spectrometry (HR-ESI-MS) analysis established
the molecular formulae as C50H64O17 for 7 (with the positive
[M + Na]+ ion at m/z = 959.40358, 959.40412 calculated) and
C50H63O17Cl for 8 (with the positive [M + Na]
+ ion at m/z =
993.36460, 993.36515 calculated), and ESI-MS-MS analysis
then narrowed their differences from CHL to the aryl groupsLtd All rights reserved
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Figure 3. Aryl Group Formation and Incorporation in CHL Biosynthesis
ChlB1 or its KR mutant (Y1540F) postmodifications of the 6-MSA or OSA moiety and its transfer to DM-CHL for affording deschloro-CHL and CHL or the
corresponding analogs 7 and 8. The dashed circle indicates the variable aryl group.
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Engineered MSAS for Spirotetronate Generation(Figure S3B). For compound 7, the 1H NMR spectrum displayed
two broad singlet aromatic protons at d 6.24 and 6.29, distinct
from the pair of ortho protons at d 6.76 and 7.37 (d, J = 8.9 Hz)
in that of CHL (Figure S3C); and the HMBC spectrum showed
cross-peaks from d 3.74 (s, CH3-9
0) to C-20, from d 6.29 (brs,
H-30) to C-10, C-20, and C-40, from d 6.24 (brs, H-50) to C-40 and
C-60, and from d 2.23 (s, CH3-80) to C-10, C-50, and C-60
(Figure S3E). Together with its 13C NMR, 1H-1H COSY, HSQC,
and ROESY spectra (Figures S3D and S3E), 7 was confirmed
to be a new deschloro-CHL derivative, which bears a 4-hydrox-
ylated aryl group originated from the OSA moiety (Figure 5).
Similar experiments were performed for compound 8, and the
key HMBC correlations established that it is a new CHL analog
possessing a 5-chlorinated OSA derivative moiety as 2-me-
thoxy-4-hydroxy-5-chloro-6-methyl-benzoyl (Figure 5; Figures
S3C and S3F).
Identification of new spirotetronates 7 and 8 in TL1077 is well
in agreement with the fact that deschloro-CHL and CHL are nor-
mally coproduced by the S. antibioticus wild-type strain (Keller-
Schierlein et al., 1969). It is remarkable, and indicative of the
effective collaboration of the KR mutant ChlB1 (Y1450F) with
downstream enzymes in the CHL biosynthetic pathway. The
conversion of DM-CHL to 7 or 8 requires O-methylation (cata-Chemistry & Biology 17,lyzed by ChlB5) and/or chlorination (catalyzed by ChlB4) to func-
tionalize the OSAmoiety, as well as two acyltransfer steps (cata-
lyzed by ChlB3 and ChlB6, respectively) in the process of its
incorporation (Figure 3) (He et al., 2009). These reactions are
strongly dependent on the specific recognitions of the proteins.
Given that the discrete ACP ChlB2 provides the structural
features in molecular recognition of the following enzymes (i.e.,
ChlB4, ChlB5, and ChlB6), the potential steric hindrance, from
the additional C-4 hydroxyl group of the OSA moiety, could be
attenuated. ChlB1 postmodifications (i.e., C-2 O-methylation
and C-5 chlorination) then take place on OSA-S-ChlB2 for matu-
ration, followed by the action of the second AT ChlB6 for
appending the modified OSA moiety onto DM-CHL. Therefore,
the engineered ChlB1 (Y1540F) should retain the ability, most
likely by its ACP domain, to interact with the first ATChlB3, allow-
ing the transfer of the OSA moiety onto ChlB2 for tailoring.
To support this hypothesis, we introducedMSS4.3, a bacterial
OSAS AviM-encoding construct (Gaisser et al., 1997), into
TL1012 to generate the recombinant strain TL1078 for
compound 7 and 8 examination. Because of the presence of
aviN (in the avi gene cluster) encoding putative AT that is highly
homologous to ChlB3 or ChlB6, the resulting OSA moiety from
AviM was speculated to be directly transferred from the495–503, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 499
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Figure 4. Validation of NewSpirotetronate Produc-
tion in S. antibioticus
HPLC analysis of fermentation cultures from the wild-type
strain (I), chlB1-inactivatedmutant TL1012 (II), and TL1077
by in trans complementation of the construct for express-
ing the KR mutant ChlB1 (Y1540F) in TL1012 (III). a, de-
schloro-CHL; b, CHL; c, DM-CHL; d, compound 7; and
e, compound 8.
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Engineered MSAS for Spirotetronate GenerationAviM-ACP domain to the molecule in avilamycin biosynthesis
(He et al., 2009). The AviM-ACP-tethered acyl group can be
hydrolyzed without the functional association of AviN, consistent
with the fact that heterologous expression of MSS4.3 in S. coeli-
color or S. lividans led to the production of the free acid OSA.
TL1078 indeed accumulated OSA (Figure S2A), confirming that
AviM is functional in this S. antibioticus strain; however, only
traces (optically invisible) of compounds 7 and 8 were detected
upon HPLC-MS analysis (Figure S2B), indicating the inefficient
incorporation of the AviM-synthesized OSA moiety. This might
be due to the unfavorable recognition between AviM-ACP and
the first AT ChlB3, which does not facilitate OSA-S-ChlB2 gener-
ation for proceeding. These findings give new insights into aryl
group formation in CHL biosynthesis, setting the stage for further
engineering of the CHL biosynthetic pathway to furnish variable
aryl functionality.7
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Figure 5. Structural Elucidation of New Spirotetronates
1H-1H COSY (for 7) and selected HMBC correlations (for 7 and 8) that establish the variable substitu
500 Chemistry & Biology 17, 495–503, May 28, 2010 ª2010 Elsevier Ltd All rights reseBioassay of New Spirotetronates 7 and 8
To evaluate the effect of substitution of the
6-MSA derivativemoiety with theOSA derivative
moiety, newly obtained compounds 7 and 8
were subjected to bioassay against the Gram-
positive test strains Bacillus subtilis and Staphy-
lococcus aureus, with the parent products
deschloro-CHL and CHL as controls. Although
B. subtilis was more sensitive to the test com-
pounds than S. aureus (Figure S4), compounds
7 and 8 were apparently bioactive and showedimproved antibacterial activities in comparison to those of
deschloro-CHL and CHL (Table 1), respectively. CHL has been
previously found to be active against Gram-positive bacteria
and fungi, and to inhibit cholesterol biosynthesis in rat liver
homogenate via the mevalonate pathway along with its deriva-
tives (Schindler and Za¨hner, 1972; Kawashima et al., 1992; Tere-
khova et al., 2008). The complete lack of the aryl group (to give
DM-CHL) led to dramatic decreases in antibacterial activity (Jia
et al., 2006). Introduction of a C-4 hydroxyl group to this aryl
moiety may at least improve water solubility, which is of impor-
tance to the bioavailability of chemotherapeutic agents in vivo.
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Table 1. Minimum Inhibitory Concentrations of Test
Spirotetronates in This Study
Organism Numbera
MIC (mg/ml)
8 CHL 7 Deschloro-CHL
Bacillus subtilis SIPI-JD1001 16 32 32 64
Staphylococcus
aureus
SIPI-JD1002 64 128 128 >128
a The test organisms were deposited at the Shanghai Institute of Pharma-
ceutical Industry (SIPI) with the given numbers.
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Engineered MSAS for Spirotetronate Generationstructural diversity. In this study, we have provided a genetic
way for alteration of the aryl functionality on the complex
spirotetronate antibiotic CHL, based on in vivo investigation
into the functions of the KR and DH domains of the bacterial
6-MSAS ChlB1 and its compatibility with downstream
enzymes for aryl moiety modification and incorporation.
Our findings support a common paradigm for 6-MSAbiosyn-
thesis in bacteria and fungi, and unveil new insights into the
process of aryl group formation that involves specific
protein recognitions in CHL biosynthesis. KR-catalyzed
selective reduction of ChlB1 is not essential for the third
two-carbon unit extension to give the tetraketide interme-
diate. Given that triketides variable in b functionality can
serve as the substrate, the promiscuity of the KS domain
of ChlB1 led to the creation of amutant for OSA biosynthesis
by replacing the key amino acid residue Tyr1450 with Phe at
the active site of the KR domain. Importantly, this engi-
neered ChlB1 is compatible with downstream enzymes for
late-stage tailoring, and their functional association allows
for further modifications of the OSA moiety and its transfers
onto the molecule, yielding the new CHL analogs 7 and 8
bearing the aryl group derived from OSA. The employed
ACP-centered strategy may facilitate specific protein-
protein interactions in the process. The newly obtained spi-
rotetronates 7 and 8 exhibit antibacterial activities, which
are comparable to, if not greater than, those of the parent
products deschloro-CHL and CHL. Incarnating the signifi-
cance of combinatorial biosynthesis methods, structural
alteration of complex natural products with densely assem-
bled functionalities (e.g., spirotetronates) can be achieved
by genetic manipulation of their biosynthetic pathways.EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, and Reagents
Bacterial strains and plasmids used in this study are summarized in Table S1.
Biochemicals, chemicals, media, restriction enzymes, and other molecular
biological reagents were purchased from standard commercial sources unless
otherwise stated.DNA Isolation, Manipulation, and Sequencing
DNA isolation and manipulation in Escherichia coli and Streptomyces were
carried out according to standard methods (Kieser et al., 2000; Sambrook
and Russell, 2001). PCR amplifications were carried out on an Authorized
Thermal Cycler (Eppendorf AG 22331) using either Taq DNA polymerase or
PfuUltra High-Fidelity DNA polymerase (Promega). Primer synthesis and
DNA sequencing were performed at Shanghai Invitrogen Biotech and the
Chinese National Human Genome Center.Chemistry & Biology 17,Sequence Analysis
The open reading frames were deduced from the sequence by using the Fra-
mePlot 4.0beta program (http://nocardia.nih.go.jp/fp4). The corresponding
deduced proteins were compared with other known proteins in the databases
by available BLAST methods (http://www.ncbi.nlm.nih.gov/blast). Amino acid
sequence alignment was performed by the CLUSTALW method, and the
DRAWTREE and DRAWGRAMmethods from BiologyWorkbench 3.2 software
(http://workbench.sdsc.edu).Heterogeneous Expression of chlB1 and Its Derivatives in S. albus
To make the chlB1 expression construct, the DNA fragments encoding indi-
vidual functional domains of ChlB1 were amplified by PCR, sequenced to
confirm the fidelity, and assembled by using a multiple-fragment ligation
strategy. A 1.5 kb PCR product encoding the KS domain was obtained by
using the primers 50-AT GAA TTC TCT AGA GGC AGC ACC CAC GTT CTG-30
(XbaI site underlined) and 50-TA TAT AAG CTT AAG GGG AAC AGC CGC
TCC GTC-30 (AflII site underlined) and cloned into pSP72, yielding pAL1081;
a 1.2 kb PCR product encoding the AT domain was obtained by using the
primers 50-TA GAA TTC CTT AAG CGG TGG AAC GCA GGC CGG-30 (AflII
site underlined) and 50-TA TAT AAG CTT AGA TCT CCG GTC GGG TGC
AGA CG-30 (HindIII and BglII sites underlined) and cloned into pSP72, yielding
pAL1082. These 1.5 kb XbaI/AflII and 1.2 kb HindIII/AflII fragments were
respectively recovered from pAL1081 and pAL1082, and then ligated with
a 0.5 kb EcoRI/XbaI fragment containing the PermE* promoter in pSP72,
yielding pAL1083, in which the 2.7 kb fragment encoding the N-terminal KS-
AT domain of ChlB1 is under the control of the PermE* promoter. On the other
hand, a 1.0 kb PCR product encoding the DH domain was obtained by using
the primers 50-TA GAA TTC AGA TCT GGT CGC CCT GCC GCT G-30 (EcoRI
and BglII sites underlined) and 50-TA TAT AAG CTT CCT AGG GTG CGC
CGC CGT CAT G-30 (AvrII site underlined) and cloned into pSP72, yielding
pAL1084; a 1.9 kb fragment encoding the KR-ACP domain was obtained by
using the primers 50-TA GAA TTC CCT AGG GAC CTG GTC TTC GAG ATG-
30 (AvrII site underlined) and 50-TA TAT AAG CTT TCA GGC CGT TGC CGC
CGG-30 (HindIII site underlined) and cloned into pSP72, yielding pAL1085.
These 1.0 kb EcoRI/AvrII and 1.8 kb AvrII/HindIII fragments were respectively
recovered from pAL1084 and pAL1085 and ligated into pSP72, yielding
pAL1086, which contains the 2.9 kb fragment encoding the C-terminal DH-
KR-ACP domain of ChlB1. Finally, the 3.2 kb EcoRI/BglII fragment from
pAL1083 and 2.9 kb BglII/HindIII fragment from pAL1086 were recovered
and cloned into pTGV2, yielding the recombinant construct pAL1087, in which
chlB1 is under the control of the PermE* promoter.
To inactivate the DH domain of ChlB1 with pAL1084, which contains a 1.0 kb
fragment encoding the DH domain as the template, PCR amplifications were
carried out by using the primers 50-C TAC CCC GGC AGC GCC ACC ATC
AAC GGC ACG-30 and 50-CGT GCC GTT GAT GGT GGC GCT GCC GGG
GTA G-30 for mutation of H947 to A, and the primers 50-C TAC CCC GGC
AGC TTC ACC ATC AAC GGC ACG-30 and 50-CGT GCC GTT GAT GGT
GAA GCT GCC GGG GTA G-30 for mutation of H947 to F, at the conserved
active site. To inactivate the KR domain of ChlB1 with pAL1085, which
contains a 1.9 kb fragment encoding the KR-ACP domain as the template,
PCR amplifications were carried out by using the primers 50-C ACC GGC
GGA CTG GCC ACC CTC GGC CTG G-30 and 50-C CAG GCC GAG GGT
GGC CAG TCC GCC GGT G-30 for mutation of G1389 to yield GxAxxG within
the NADPH-binding motif, the primers 50-C ACC GGC GCA CTG CCC ACC
CTC GCC CTG G-30 and 50-C CAG GGC GAG GGT GGG CAG TGC GCC
GGT G-30 for mutation of G1387, G1389, and G1392 to yield AxPxxA, and
the primers 50-GGC CAG GCC GCC TTC GGC TCC GCC AAC G-30 and
50-C GTT GGC GGA GCC GAA GGC GGC CTG GCC-30 for mutation of
Y1540 to F at the conserved active site. Using the similar multiple-fragment
ligation strategy described above, each mutant DNA fragment was assembled
with the fragments encoding other functional domains, yielding the recombi-
nant constructs pAL1088 for expressing the DH mutant ChlB1 (H947A),
pAL1089 for expressing the DH mutant (H947F), pAL1090 for expressing the
KR mutant (G1389A), pAL1091 for expressing the KR mutant (G1387A,
G1389P, and G1392A), and pAL1092 for expressing the KR mutant (Y1540F).
Introduction of each plasmid DNA into S. albus was carried out by E. coli-
Streptomyces conjugation following the procedure described previously495–503, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 501
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as the recombinant strains.Production, Isolation, and Analysis of 6-MSA and OSA in S. albus
Fermentation of the S. albus strains and isolation and HPLC-MS analysis of
their products were carried out according to themethods described previously
(Shao et al., 2006; Zhao et al., 2008). The HR-EI-MS analyses were performed
on aWatersMicromassGCT (monoisotopicmass, odd and even electron ions)
mass spectrometer, establishing the molecular formulae as C8H8O3 for 6-MSA
(with the M+ ion atm/z = 152.0477, 152.0473 calculated) and C8H8O4 for OSA
(with the M+ ion at m/z = 168.0424, 168.0424 calculated). The standards OSA
and TAL were purchased from Sigma-Aldrich.Production, Isolation, and Analysis of Spirotetronates
in S. antibioticus
Introduction of the recombinant plasmids pAL1092 encoding the KR mutant
ChlB1 (Y1450F) and MSS4.3 encoding AviM into the S. antibioticus strain
AL1012 (for DM-CHL production) was performed using the method described
previously (Jia et al., 2006).
Fermentation of the S. antibioticus strains and isolation and HPLC-MS anal-
ysis of their products were carried out according to the methods described
previously (Jia et al., 2006). NMR spectra for new spirotetronates 7 and 8,
along with CHL, were measured on a Bruker AV500/125 spectrometer
(Supplemental Information). For 7, 1H and 13C NMR assignments are listed
in Table S2; HR-ESI-MS m/z [M + Na]+ 959.40358 (calculated for
C50H64O17Na
+, 959.40412). For 8, 1H NMR (500 Hz, CDCl3) d 2.34 (s, 3H, 8
0),
3.81 (s, 3H, 90), 4.52 (d, J = 9.0 Hz, 1H, 100 0), 4.64 (d, J = 9.0 Hz, 1H, 100), 5.02
(m, 1H, 300), 5.17 (m, 1H, 17), 5.41 (m, 1H, 16), 5.59 (m, 1H, 10), 5.70 (d, J =
10.5 Hz, 1H, 9), 6.53 (s, 1H, 30), 6.82 (brs, 1H, 19); and 13C NMR (125 Hz,
CDCl3) d 177.8 (C, 1), 47.7 (C, 2), 38.1 (CH, 3), 28.2 (CH2, 4), 24.4 (CH2, 5),
36.3 (CH2, 6), 74.2 (CH, 7), 43.9 (CH, 8), 123.5 (CH, 9), 130.3 (CH, 10), 46.9
(CH, 11), 32.4 (CH2, 12), 28.2 (CH2, 13), 26.7 (CH2, 14), 33.3 (CH2, 15), 139.4
(CH, 16), 127.1 (CH, 17), 46.3 (CH, 18), 138.4 (CH, 19), 135.4 (C, 20),
27.2 (CH, 21), 35.2 (CH2, 22), 80.6 (C, 23), 165.1 (C, 24), 124.4 (C, 25), 167.1
(C, 26), 17.4 (CH3, 27), 172.6 (C, 28), 18.0 (CH3, 29), 113.0 (C, 1
0), 156.2
(C, 20), 100.6 (CH, 30), 153.5 (C, 40), 116.7 (C, 50), 135.4 (C, 60), 159.6 (C, 70),
100.6 (CH, 100), 38.1 (CH2, 200), 74.9 (CH, 300), 83.3 (CH, 400), 72.2 (CH, 500),
17.6 (CH3, 6
00), 101.3 (CH, 100 0 ), 28.6 (CH2, 200 0), 70.2 (CH, 300 0), 88.6 (CH, 400 0),
70.2 (CH, 500 0), 17.0 (CH3, 600 0); HR-ESI-MSm/z [M +Na]
+ 993.36460 (calculated
for C50H63O17ClNa
+, 993.36515).In Vitro Susceptibility Testing
To detect the biological activities of spirotetronates against S. subtilis and S.
aureus, 1, 2, 4, or 8 mg of each compound in 200 ml of methanol was added
to stainless steel cylinders on Antibiotic Medium 2 (SCAS EcoScience Tech-
nology) agar plates that were preseeded with an overnight culture of the test
strain at a concentration of 1% (vol/vol). The plates were incubated at 37C
for 24 hr, and the biological activity was estimated by measuring the sizes of
the inhibition zones. All assays were carried out in triplicate.
To determine the minimum inhibitory concentrations (MICs), antibacterial
activity was measured by broth dilution according to the method described
previously (Pucci et al., 2004). Each test compound that was dissolved in
dimethyl sulfoxide was diluted in water to produce a stock solution (256
mg/ml). Fifty microliters of the stock solution was serially diluted into Mueller-
Hinton broth (Qingdao Hope Bio-Technology) in a 96-well microtiter plate. Fifty
microliters of the test strain (1.53 108 cfu/ml) was then added to each well of
the microtiter plate. After incubation at 37C for 18–24 hr, the MIC was deter-
mined to be the lowest concentration of compound that inhibited visible bacte-
rial growth. All testing was carried out in duplicate.SUPPLEMENTAL INFORMATION
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